280 related articles for article (PubMed ID: 29043374)
21. Management of Overactive Bladder Symptoms After Radical Prostatectomy.
Peyronnet B; Brucker BM
Curr Urol Rep; 2018 Oct; 19(12):95. PubMed ID: 30306278
[TBL] [Abstract][Full Text] [Related]
22. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
23. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
24. Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.
Balchandra P; Rogerson L
Int Urogynecol J; 2014 Aug; 25(8):1059-64. PubMed ID: 24633067
[TBL] [Abstract][Full Text] [Related]
25. [Therapy-refractory overactive bladder: alternative treatment approaches].
Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
[TBL] [Abstract][Full Text] [Related]
26. Overactive bladder: diagnosis and management.
Robinson D; Cardozo L
Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
[TBL] [Abstract][Full Text] [Related]
27. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
28. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
29. Actual treatment of overactive bladder and urge urinary incontinence.
Cornu JN
Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
[TBL] [Abstract][Full Text] [Related]
30. [Treatment for refractory non-neurogenic overactive bladder].
Gamé X; Phé V
Prog Urol; 2020 Nov; 30(14):920-930. PubMed ID: 33220820
[TBL] [Abstract][Full Text] [Related]
31. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
32. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
Yang G; Xu Y; Qu G; Zhang Y
PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
[TBL] [Abstract][Full Text] [Related]
33. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder.
Watanabe JH; Campbell JD; Ravelo A; Chancellor MB; Kowalski J; Sullivan SD
Urology; 2010 Oct; 76(4):835-40. PubMed ID: 20430422
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome.
Dobberfuhl AD
Neurourol Urodyn; 2022 Nov; 41(8):1958-1966. PubMed ID: 35607890
[TBL] [Abstract][Full Text] [Related]
35. Managing overactive bladder.
Robinson D; Cardozo L
Climacteric; 2019 Jun; 22(3):250-256. PubMed ID: 31034265
[TBL] [Abstract][Full Text] [Related]
36. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
37. Medical treatment of female overactive bladder syndrome and treatment-related effects.
Hsiao SM; Lin HH
J Formos Med Assoc; 2018 Oct; 117(10):871-878. PubMed ID: 29398096
[TBL] [Abstract][Full Text] [Related]
38. [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity].
Leicht W; Hampel C; Thüroff J
Urologe A; 2012 Mar; 51(3):348-51. PubMed ID: 22399111
[TBL] [Abstract][Full Text] [Related]
39. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
40. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Ellsworth P
Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
